Jafri Hasan's Form 4 filing
Aridis Pharmaceuticals, Inc. (ARDS) · filed Sep 8, 2021
- Accession no.
- 0001104659-21-113792
- Filed
- Sep 8, 2021
- Trade date
- Sep 3-7, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $21.1K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jafri HasanCIK 0001815352 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2021 | Common Stock | PPurchaseAcquired | +3,009 | $4.15 | +$12,487.35 | 3,009 | Direct | |
| Sep 7, 2021 | Common Stock | PPurchaseAcquired | +1,991 | $4.15 | +$8,262.65 | 5,000 | Direct | |
| Sep 7, 2021 | Common Stock | PPurchaseAcquired | +100 | $3.97 | +$397 | 5,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.